Atara losses grew in Q2
Atara Biotherapeutics swallowed more losses in the second quarter of 2021, as the early-stage company hopes for good news for its tab-cel therapy in early 2022. Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Oaks, had a net loss of $83.7 million in the second Read More →
Amgen shrugs off tough quarter, announces plans for new plant in North Carolina
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our View: Vaccines still our best weapon against COVID
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Inogen shares plummet after news of supply chain problems
Shares of the Goleta-based medical device company Inogen dropped by 27% on Aug. 5, the day after the company released its second quarter 2021 earnings. Though the maker of portable oxygen concentrators saw big increases in both revenue and earnings, uncertainty brought on by the semiconductor chip shortage led to a huge selloff of Inogen Read More →
Inogen sees revenue growth, but stock declines after report
Inogen, a Goleta-based medical device company specializing in portable oxygen concentrators, is starting to see its core business come back from the pandemic, and the company highlighted double-digit year-over-year growth in both earnings and revenue in its second quarter financial results, released Aug. 4. The company more than doubled its net income for the quarter Read More →
Amgen reports Q2 earnings decline
Amgen saw a 73% decline in net earnings in the second quarter of 2021, the company announced Aug. 3. Thousand Oaks-based Amgen, one of the world’s largest biotechnology companies, reported earnings per share of 81 cents for the quarter ended June 30, down from $3.05 per share in the same quarter last year. According to Read More →
With merger, ImmPact Bio plans growth and a move to LA
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
